| Pharmaceutical price controls and entry strategies MK Kyle The Review of Economics and Statistics 89 (1), 88-99, 2007 | 399 | 2007 |
| Pharmaceutical Investments Before and After TRIPS M Kyle The Review of Economics and Statistics, 2011 | 241* | 2011 |
| Generic competition and market exclusivity periods in pharmaceuticals HG Grabowski, M Kyle Managerial and Decision Economics 28 (4‐5), 491-502, 2007 | 207 | 2007 |
| Public & private spillovers, location and the productivity of pharmaceutical research JL Furman, MK Kyle, IM Cockburn, R Henderson National Bureau of Economic Research, 2006 | 175 | 2006 |
| Did US bank supervisors get tougher during the credit crunch? Did they get easier during the banking boom? Did it matter to bank lending? AN Berger, MK Kyle, JM Scalise Prudential Supervision: What Works and What Doesn't, 301-356, 2001 | 164 | 2001 |
| Surviving the gales of creative destruction: The determinants of product turnover JM De Figueiredo, MK Kyle Strategic Management Journal 27 (3), 241-264, 2006 | 149* | 2006 |
| Deregulating Direct‐to‐Consumer Marketing of Prescription Drugs: Effects on Prescription and Over‐the‐Counter Product Sales* DC Ling, ER Berndt, MK Kyle Journal of Law and Economics 45 (S2), 691-723, 2002 | 138 | 2002 |
| The role of firm characteristics in pharmaceutical product launches MK Kyle The RAND journal of economics 37 (3), 602-618, 2006 | 137 | 2006 |
| Markets for pharmaceutical products FS Morton, M Kyle Handbook of health economics 2, 763-823, 2011 | 127 | 2011 |
| The Long Shadow of Patent Expiration. Generic Entry and Rx-to-OTC Switches ER Berndt, M Kyle, D Ling Scanner Data and Price Indexes, 229-274, 2003 | 122* | 2003 |
| Intellectual property protection and the geography of trade M Delgado, M Kyle, AM McGahan The Journal of Industrial Economics 61 (3), 733-762, 2013 | 117 | 2013 |
| The more we die, the more we sell? a simple test of the home-market effect A Costinot, D Donaldson, M Kyle, H Williams The quarterly journal of economics 134 (2), 843-894, 2019 | 113 | 2019 |
| Strategic responses to parallel trade M Kyle The BE Journal of Economic Analysis & Policy 11 (2), 2011 | 98* | 2011 |
| Intellectual property rights and access to innovation: evidence from TRIPS M Kyle, Y Qian National Bureau of Economic Research, 2014 | 83 | 2014 |
| Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets B Waning, M Kyle, E Diedrichsen, L Soucy, J Hochstadt, T Bärnighausen, ... Globalization and Health 6, 1-19, 2010 | 81 | 2010 |
| Objective and self‐report work performance measures: a comparative analysis G Pransky, S Finkelstein, E Berndt, M Kyle, J Mackell, D Tortorice International Journal of Productivity and Performance Management 55 (5), 390-399, 2006 | 79 | 2006 |
| Competition and the efficiency of markets for technology ML Allain, E Henry, M Kyle Management Science 62 (4), 1000-1019, 2016 | 76* | 2016 |
| 11. Mergers and alliances in pharmaceuticals: effects on innovation and R&D productivity H Grabowski, M Kyle The economics of corporate governance and mergers 262, 2008 | 71 | 2008 |
| Would greater transparency and uniformity of health care prices benefit poor patients? MK Kyle, DB Ridley Health Affairs 26 (5), 1384-1391, 2007 | 67 | 2007 |
| Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act HG Grabowski, M Kyle, R Mortimer, G Long, N Kirson Health Affairs 30 (11), 2157-2166, 2011 | 62 | 2011 |
